Dr. Reddy’s Laboratories Ltd ADR (RDY) Shares Outstanding 2007–TTM

Name: Dr. Reddy’s Laboratories Ltd ADR (RDY) shares outstanding history 2007-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-07-29

Dr. Reddy’s Laboratories Ltd ADR annual shares outstanding for fiscal TTM was 833 million shares, an increase of 0.0% from 833 million shares in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

RDY Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-06-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31	2016-03-31	2015-03-31	2014-03-31	2013-03-31	2012-03-31	2011-03-31	2010-03-31	2009-03-31	2008-03-31	2007-03-31
Shares Outstanding (M)	833M	833M	834M	834M	832M	832M	832M	830M	831M	831M	835M	855M	855M	853M	852M	851M	850M	848M	842M	843M	796M

INR; INRM / INRB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RDY Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Shares Outstanding (M)	833M	835M	833M	833M	833M	834M	834M	834M

INR; INRM / INRB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

UTHR Shares Outstanding — United Therapeutics Corporation
NBIX Shares Outstanding — Neurocrine Biosciences Inc
ELAN Shares Outstanding — Elanco Animal Health
ALKS Shares Outstanding — Alkermes Plc
HIMS Shares Outstanding — Hims Hers Health Inc

More RDY metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All RDY financial statements → Interactive RDY charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.